Small-Molecule Drugs: The Innovation Battle

Small molecules again dominated new drug approvals by the FDA in 2021, but which companies had approvals? Is innovation coming from the large or small companies?

Small molecules again dominated new drug approvals by the FDA in 2021, but which companies had approvals? Is innovation coming from the large or small companies?

Product mix of new drug approvals in 2021
In terms of product mix, small-molecule drugs dominated approvals of new molecular entities (NMEs) by the US Food and Drug Administration’s Center for Drug Evaluation and Research in 2021. Of the 50 NMEs approved in 2021, 36, or 72%, were small molecules, and 14, or 28%, were biologics. This continues a recent trend of having approximately three-fourths of NME approvals be small molecules. In 2020, 75% or 40 of the 53 NMEs were small molecules. In 2019, 79% of NME approvals were small molecules; in 2018, it was 71% and 74% in 2017.

Big Pharma and small-molecule drug approvals
Of the 36 small molecules approved as NMEs in 2021, the large pharmaceutical companies accounted for 13, or 36%, of the NME small-molecule approvals in 2021 (see Figure 1). 

Smaller companies and new small-molecule approvals
Meanwhile, small companies accounted for 23, or 64% of the small-molecule NME approvals in 2021 (see Figure 2).

Small-molecule NME approvals: keeping with historical trends
The dominance of small-molecule new drug approvals in 2021 was consistent with historical levels over the past five years, which has seen relatively stable levels of the number of small-molecules and biologics approved (see Figure 3).

Recent Feature Articles

Incentivizing US-Based Contract Biomanufacturing 

By
The Biotechnology Innovation Organization (BIO) is recommending a seven-point action plan to increase US competitiveness in biotech, including incentives for increasing US-based contract biomanufacturing.

The Next Round in the Obesity Drug Market 

By
Pfizer’s move to secure $1.5 billion in funding from the investment firm, Blackstone, to advance its late-stage GLP-1 candidate is heating up the obesity drug market. A look at the revenue leaders and contenders.

CDMO Moves: Lonza Increasing Position in US

By
Lonza is increasing its position in the US with a pending acquisition of five CDMO sites from the life-sciences business of Merck KGaA. What sites and capabilities is the company gaining in the deal?

Orphan Drugs: The Top Products & Companies

By
Orphan drug sales are projected to reach a peak of 30% of the global prescription drug market by 2027 and sales of $400 billion by 2032. What products and companies are leading growth?